New drug MBS8(1V270) enters human testing for advanced cancers

NCT ID NCT04855435

First seen Mar 05, 2026 · Last updated May 14, 2026 · Updated 11 times

Summary

This early-stage study tests a new drug called MBS8(1V270) in about 106 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. Researchers will also look for early signs that the drug shrinks tumors. Participants must have a tumor that can be biopsied and be willing to follow the study schedule.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centro Integral Oncológico Clara Campal (CIOCC)

    RECRUITING

    Madrid, 28050, Spain

    Contact

  • Consorcio Hospital General Universitario de Valencia

    RECRUITING

    Valencia, Spain

    Contact

  • Fundacion Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (FJD)

    RECRUITING

    Madrid, 28015, Spain

    Contact

  • Herlev and Gentofte Hospital, Center for Cancer Research

    RECRUITING

    Herlev, DK-2730, Denmark

    Contact

  • Institut Catalá de Oncologia - Hospital Duran i Reynals.

    NOT_YET_RECRUITING

    Barcelona, Spain

    Contact

Conditions

Explore the condition pages connected to this study.